In short
- Tirzepatide activates two receptors – for GIP and for GLP-1 – which is why it is called a dual agonist.
- In the EU, Mounjaro is approved for type 2 diabetes and for weight management in obesity, or overweight with a related condition.
- In SURMOUNT-1, body weight fell on average by 15.0% to 20.9% over 72 weeks depending on the dose level (placebo: 3.1%).
- Drug class
- GIP/GLP-1 receptor agonist
- Product (EU)
- Mounjaro
- Given
- weekly (pen)
- Prescription
- required
What is tirzepatide?
Tirzepatide is the active ingredient in Mounjaro. It is a man-made peptide that binds to two receptors at once: the receptor for GLP-1 (glucagon-like peptide 1) and the receptor for GIP (glucose-dependent insulinotropic polypeptide). Both hormones are incretins – gut hormones released after a meal that help the body release insulin. That is why tirzepatide is often called a "dual agonist". How much the extra GIP action adds to the overall effect is still being researched.
Approval in the EU
Mounjaro has been authorised in the EU since 2022, first for adults with type 2 diabetes alongside diet and exercise. Weight management was added later: according to the EMA, for adults with obesity (BMI of 30 or more) or with overweight (BMI from 27 to under 30) plus at least one weight-related condition such as high blood pressure, raised blood lipids or type 2 diabetes.
| Feature | Mounjaro (tirzepatide) |
|---|---|
| Mechanism | dual GIP and GLP-1 receptor agonist |
| How it is given | pre-filled pen, injected under the skin once a week |
| Approved for (EU) | type 2 diabetes; weight management in obesity, or overweight with a related condition |
| Prescription | required |
Treatment starts at a low dose that is raised step by step. Which dose is right and when it is increased is decided by the treating doctor. The term titration explains why this is done gradually.
How tirzepatide works
- Blood glucose: tirzepatide boosts insulin release when blood glucose is raised and lowers the release of glucagon.
- Stomach: emptying slows down, so the feeling of fullness lasts longer.
- Appetite: many people feel less hungry and eat smaller amounts.
The first lesson of the GLP-1 basics course walks through this mechanism step by step.
What the trials show
SURMOUNT-1 was the pivotal weight-management trial: 2,539 adults with obesity, or with overweight and a related condition, but without diabetes, received one of three tirzepatide dose levels or placebo for 72 weeks, each alongside lifestyle counselling. Body weight fell on average by 15.0% (lowest level), 19.5% (middle level) and 20.9% (highest level), compared with 3.1% on placebo. According to the EMA, more than 85% of people on tirzepatide lost at least 5% of their weight, versus 35% on placebo.
SURPASS-2 compared tirzepatide with semaglutide 1 mg in 1,879 adults with type 2 diabetes already taking metformin. After 40 weeks, HbA1c fell by 2.01 to 2.30 percentage points depending on the tirzepatide dose, and by 1.86 points on semaglutide. Weight also dropped more with tirzepatide.
In the head-to-head SURMOUNT-5 trial in 751 adults with obesity but no diabetes, participants lost on average 20.2% of their weight over 72 weeks on tirzepatide and 13.7% on semaglutide. For the full picture, see semaglutide vs. tirzepatide.
Common side effects and warnings
According to the EMA, digestive problems are among the most common side effects – mainly nausea and diarrhoea, along with constipation and vomiting. They are usually mild to moderate and occur mostly when the dose is changed. The product information also mentions, among other things:
- low blood glucose when tirzepatide is used together with insulin or a sulphonylurea,
- warnings about pancreatitis (get persistent severe abdominal pain checked straight away),
- slower stomach emptying, which can affect how other oral medicines are absorbed – mention it if you take the contraceptive pill or other tablets,
- advice to stop tirzepatide at least one month before a planned pregnancy because it stays in the body for a long time – something to plan with your doctor.
What shows up in blood tests
In the diabetes trials, HbA1c and blood glucose go down – which is the intended effect. Among investigation findings, the product information also lists increases in the digestive enzymes lipase and amylase and a higher heart rate. A single raised value without symptoms does not automatically point to a disease, but it should be interpreted together with your doctor.
Because many people eat considerably less on tirzepatide, it is also worth keeping an eye on values that depend on diet, such as iron stores, vitamin B12 or kidney function. Eating enough protein helps preserve muscle while losing weight – the protein calculator shows your range.
In the BeBetr app you can log your prescribed therapy, get reminders for your schedule and see weight and lab results side by side over time – so changes stand out earlier and you have everything to hand at your next appointment.
Doses, injection sites and supply at a glance
Document your prescribed therapy: reminders, injection-site rotation, vials and history – privately synced.
Frequently asked questions
Is Mounjaro the same as Ozempic?
No. Ozempic contains semaglutide, which only acts on the GLP-1 receptor. Mounjaro contains tirzepatide, which also acts on the GIP receptor. The semaglutide vs. tirzepatide comparison explains the differences.
How quickly does tirzepatide work?
Many people notice less appetite within the first weeks. The effect on weight and HbA1c builds over months – SURMOUNT-1 measured it over 72 weeks.
Which blood tests make sense on tirzepatide?
That is up to your doctor. Common ones include HbA1c, kidney and liver values, blood lipids and diet-dependent markers such as ferritin and vitamin B12.
Sources
- EMA: Mounjaro (tirzepatide) – product information
- Jastreboff AM et al.: Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022
- Frías JP et al.: Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med 2021
- Aronne LJ et al.: Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med 2025
Written by the BeBetr editorial team with AI assistance; facts checked against the sources listed (as of Nov 22, 2026). This content is for information only and does not replace medical advice, diagnosis or treatment.
BeBetr